Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

Graeme J Hankey; Manesh R Patel; Susanna R Stevens; Richard C Becker; Günter Breithardt; Antonio Carolei; Hans-Christoph Diener; Geoffrey A Donnan; Jonathan L Halperin; Kenneth W Mahaffey; Jean-Louis Mas; Ayrton Massaro; Bo Norrving; Christopher C Nessel; John F Paolini; Risto O Roine; Daniel E Singer; Lawrence Wong; Robert M Califf; Keith A A Fox; Werner Hacke; ROCKET AF Steering Committee Investigators

doi:10.1016/S1474-4422(12)70042-X

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

Graeme J Hankey, Manesh R Patel, Susanna R Stevens, Richard C Becker, Günter Breithardt, Antonio Carolei, Hans-Christoph Diener, Geoffrey A Donnan, Jonathan L Halperin, Kenneth W Mahaffey, Jean-Louis Mas, Ayrton Massaro, Bo Norrving, Christopher C Nessel, John F Paolini, Risto O Roine, Daniel E Singer, Lawrence Wong, Robert M Califf, Keith A A FoxWerner Hacke, ROCKET AF Steering Committee Investigators

350 Citations (Scopus)

Abstract

In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA).

Original language	English
Journal	Lancet Neurology Network
Volume	11
Issue number	4
Pages (from-to)	315-22
Number of pages	8
ISSN	1470-8582
DOIs	https://doi.org/10.1016/S1474-4422(12)70042-X
Publication status	Published - Apr 2012

Keywords

Aged
Anticoagulants
Atrial Fibrillation
Double-Blind Method
Humans
Intention to Treat Analysis
Ischemic Attack, Transient
Morpholines
Multicenter Studies as Topic
Recurrence
Stroke
Thiophenes
Treatment Outcome
Warfarin

Access to Document

10.1016/S1474-4422(12)70042-X

Cite this

Hankey, G. J., Patel, M. R., Stevens, S. R., Becker, R. C., Breithardt, G., Carolei, A., Diener, H.-C., Donnan, G. A., Halperin, J. L., Mahaffey, K. W., Mas, J.-L., Massaro, A., Norrving, B., Nessel, C. C., Paolini, J. F., Roine, R. O., Singer, D. E., Wong, L., Califf, R. M., ... ROCKET AF Steering Committee Investigators (2012). Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurology Network, 11(4), 315-22. https://doi.org/10.1016/S1474-4422(12)70042-X

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. / Hankey, Graeme J; Patel, Manesh R; Stevens, Susanna R et al.
In: Lancet Neurology Network, Vol. 11, No. 4, 04.2012, p. 315-22.

Research output: Contribution to journal › Journal article › Research › peer-review

Hankey, GJ, Patel, MR, Stevens, SR, Becker, RC, Breithardt, G, Carolei, A, Diener, H-C, Donnan, GA, Halperin, JL, Mahaffey, KW, Mas, J-L, Massaro, A, Norrving, B, Nessel, CC, Paolini, JF, Roine, RO, Singer, DE, Wong, L, Califf, RM, Fox, KAA, Hacke, W & ROCKET AF Steering Committee Investigators 2012, 'Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF', Lancet Neurology Network, vol. 11, no. 4, pp. 315-22. https://doi.org/10.1016/S1474-4422(12)70042-X

@article{d145bbebd8da4be2a66c988b6ee9e621,

title = "Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF",

abstract = "In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA).",

keywords = "Aged, Anticoagulants, Atrial Fibrillation, Double-Blind Method, Humans, Intention to Treat Analysis, Ischemic Attack, Transient, Morpholines, Multicenter Studies as Topic, Recurrence, Stroke, Thiophenes, Treatment Outcome, Warfarin",

author = "Hankey, \{Graeme J\} and Patel, \{Manesh R\} and Stevens, \{Susanna R\} and Becker, \{Richard C\} and G{\"u}nter Breithardt and Antonio Carolei and Hans-Christoph Diener and Donnan, \{Geoffrey A\} and Halperin, \{Jonathan L\} and Mahaffey, \{Kenneth W\} and Jean-Louis Mas and Ayrton Massaro and Bo Norrving and Nessel, \{Christopher C\} and Paolini, \{John F\} and Roine, \{Risto O\} and Singer, \{Daniel E\} and Lawrence Wong and Califf, \{Robert M\} and Fox, \{Keith A A\} and Werner Hacke and \{ROCKET AF Steering Committee Investigators\} and Torp-Pedersen, \{Christian Tobias\}",

year = "2012",

month = apr,

doi = "10.1016/S1474-4422(12)70042-X",

language = "English",

volume = "11",

pages = "315--22",

journal = "Lancet Neurology Network",

issn = "1470-8582",

publisher = "TheLancet Publishing Group",

number = "4",

}

TY - JOUR

T1 - Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack

T2 - a subgroup analysis of ROCKET AF

AU - Hankey, Graeme J

AU - Patel, Manesh R

AU - Stevens, Susanna R

AU - Becker, Richard C

AU - Breithardt, Günter

AU - Carolei, Antonio

AU - Diener, Hans-Christoph

AU - Donnan, Geoffrey A

AU - Halperin, Jonathan L

AU - Mahaffey, Kenneth W

AU - Mas, Jean-Louis

AU - Massaro, Ayrton

AU - Norrving, Bo

AU - Nessel, Christopher C

AU - Paolini, John F

AU - Roine, Risto O

AU - Singer, Daniel E

AU - Wong, Lawrence

AU - Califf, Robert M

AU - Fox, Keith A A

AU - Hacke, Werner

AU - ROCKET AF Steering Committee Investigators

AU - Torp-Pedersen, Christian Tobias

PY - 2012/4

Y1 - 2012/4

N2 - In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA).

AB - In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA).

KW - Aged

KW - Anticoagulants

KW - Atrial Fibrillation

KW - Double-Blind Method

KW - Humans

KW - Intention to Treat Analysis

KW - Ischemic Attack, Transient

KW - Morpholines

KW - Multicenter Studies as Topic

KW - Recurrence

KW - Stroke

KW - Thiophenes

KW - Treatment Outcome

KW - Warfarin

UR - https://www.scopus.com/pages/publications/84858621485

U2 - 10.1016/S1474-4422(12)70042-X

DO - 10.1016/S1474-4422(12)70042-X

M3 - Journal article

C2 - 22402056

SN - 1470-8582

VL - 11

SP - 315

EP - 322

JO - Lancet Neurology Network

JF - Lancet Neurology Network

IS - 4

ER -

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this